Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options$1. .$1
Biopharmaceuticals β’ Pain β’ CNS β’ Narcolepsy β’ Major Depressive Disorder
201 - 500
π° $200M Post-IPO Equity on 2019-12
September 27
201 - 500
Manage healthcare provider engagement strategies for Axsome's CNS therapies.
πΊπΈ United States β Remote
π΅ $180k - $225k / year
π° $200M Post-IPO Equity on 2019-12
β° Full Time
π΄ Lead
π Director